Pharmaceuticals
YS Biopharma Announces Name Change to LakeShore Biopharma
GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...
2024-05-24 19:30
3272
61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals
STOCKHOLM, May 24, 2024 /PRNewswire/ -- A pioneering study, presented today at the 61st ERA Congress, has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidn...
2024-05-24 19:00
4464
Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting
* The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options. * Updated results from the ELECTRA study, evaluating elacestrant in combination with abemaciclib regardless of metastatic site,show a sa...
2024-05-24 17:36
5765
CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website
* CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development. * First-in-human study data show that CS5001 is well tolerated with promising anti-tumor activ...
2024-05-24 13:00
4354
Antengene To Present One Oral and Four Abstracts at ASCO 2024
* Oral Presentation：a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in patients with cervical cancer * Three Poster presentations: Phase I/II studies of ATG-031 (anti-CD24 monoclonal antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and selinexor(XPO1 Inh...
2024-05-24 08:30
4037
Guo Guangchang: Fosun Steadfastly Focuses on Innovation + Globalization
HONG KONG, May 23, 2024 /PRNewswire/ -- The 4th BEYOND International Technology Innovation Expo (BEYOND Expo 2024) commenced with a spectacular opening ceremony on 22 May at the Venetian Theatre in the Venetian Macao. At the opening ceremony, Guo Guangchang, Chairman of Fosun International, said ...
2024-05-23 18:31
5440
Bionoxx to Highlight Innovative Strategy for Addressing Immune-Related Diseases at 2024 BIO International Conference
Corporate presentation scheduled for Tuesday, 04 June 2024 at 4:00 PM PT SAN DIEGO and SEOUL, South Korea, May 23, 2024 /PRNewswire/ -- Bionoxx Inc., an innovative biotech company developing neutrophil-directed T cell modulation technology, announced today it will unveil its novel immunomodulator...
2024-05-23 08:00
2872
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of HER3/TROP2 Bispecific ADC Drug JSKN016
SUZHOU, China, May 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (JSKN016-101) of JSKN016, a novel bispecific antibody-drug conjugate (ADC) targeting HER3 and TROP2, in the treatment of ...
2024-05-22 09:16
3412
YS Biopharma Announces Results of Extraordinary General Meeting
GAITHERSBURG, Md., May 22, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...
2024-05-22 04:15
4179
New CAS BioFinder Discovery Platform empowers drug discovery scientists to reveal insights, drive innovation, and save time
Transformative new scientific information capabilities combine an unparalleled collection of curated science data with advanced predictive models to accelerate early-stage drug discovery innovation COLUMBUS, Ohio, May 21, 2024 /PRNewswire/ -- Today, CAS, a division of the American Chemical Socie...
2024-05-21 21:00
3960
RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome
YANTAI, China, May 21, 2024 /PRNewswire/ -- RemeGen Co. Ltd.
2024-05-21 17:35
2983
Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease
SAN FRANCISCO and SUZHOU, China, May 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and ot...
2024-05-21 08:55
4319
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
* CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer. * Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under pre-clinical evaluation for multiple cancer...
2024-05-21 07:58
2631
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
SAN FRANCISCO and SUZHOU, China, May 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2024-05-20 08:20
4396
LiveSpo Pharma Emerges as Vietnam's Pioneer at Vitafoods Europe 2024, Unveiling Groundbreaking Research and Product Development to Reduce Antibiotic Use in Digestive and Respiratory Care
HANOI, Vietnam, May 17, 2024 /PRNewswire/ -- LiveSpo Pharma is the first Vietnamese entity to report on clinical studies at Vitafoods Europe 2024, held inGeneva, Switzerland. LiveSpo Pharma showcased its range of high-concentration, multi-strain liquid medical probiotics products, affirming the ...
2024-05-17 18:33
6473
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
Australian animal health leader adopts Veeva Vault QualityDocs and Veeva Vault
Training for greater efficiency and compliance
SYDNEY, May 17, 2024 /PRNewswire/ -- Troy Animal Healthcare and Veeva Systems
2024-05-17 07:00
17730
Seegene and Springer Nature Announce Strategic Alliance
- Strategic alliance aims to foster collaboration with researchers working in various disease fields by using best-in-class PCR diagnostic technology - Companies will facilitate C-level cooperation, strengthening the partnership for the SG OneSystem™ business (Seegene's technology-sharing busine...
2024-05-16 21:00
4899
Fosun International Earns a Spot on "2024 Fortune China ESG Impact List"
HONG KONG, May 16, 2024 /PRNewswire/ -- On 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the list, highlighting its outstanding performance and industry...
2024-05-16 11:15
5297
Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China
SHANGHAI, May 14, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced that NEFECON®, a delayed rel...
2024-05-14 21:41
4164
SCG Cell Therapy Presented New Preclinical Data in an Oral Presentation at ASGCT 2024 Annual Meeting Highlighting Superior Tumor Inhibition of its Immunoswitch Armored HPV-TCR T Cell Therapy (SCG142) against a Broad Range of HPV-associated Cancers
SINGAPORE, May 13, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced first preclinical data of its novel human papillomavirus (HPV)-specific T cell receptor-...
2024-05-13 10:00
4282
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 294 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
9295
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
7719
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
2026-09-17 13:09
6962
CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
2026-09-15 19:07
6289
